Preventive effect of TU-100 on a type-2 model of colitis in mice: Possible involvement of enhancing adrenomedullin in intestinal epithelial cells

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Kaneko, Atsushi ^a   Kono, Toru ^b,c   Miura, Naoko ^a   Tsuchiya, Naoko ^a   Yamamoto, Masahiro ^a  

^a TSUMURA AND CO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Sapporo Higashi Tokushukai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(6) GINGEROL; ADRENOMEDULLIN; GAMMA INTERFERON; GASTROINTESTINAL AGENT; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RG 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXY ALPHA SANSHOOL; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MALTOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXAZOLONE; PLANT MEDICINAL PRODUCT; SHOGAOL; TU 100; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHOXYLIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; COLITIS; COLON INJURY; DRUG ACTIVITY; DRUG EFFECT; ENZYME IMMUNOASSAY; INTESTINE EPITHELIUM CELL; INTESTINE ULCER; MALE; MORBIDITY; MOUSE; NONHUMAN; RAT; TRADITIONAL MEDICINE; WEIGHT REDUCTION;

EID: 84890092387     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/384057     Document Type: Article

References (44)

1. Strober W., Fuss I., Mannon P., The fundamental basis of inflammatory bowel disease. Journal of Clinical Investigation 2007 117 3 514 521 2-s2.0-33847381116 10.1172/JCI30587 (Pubitemid 46348505)
2. Ibrahim C. B., Aroniadis O. C., Brandt L. J., On the role of ischemia in the pathogenesis of IBD: a review. Inflammatory Bowel Diseases 2010 16 4 696 702 2-s2.0-77949515552 10.1002/ibd.21061
3. Kono T., Kanematsu T., Kitajima M., Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery 2009 146 5 837 840 2-s2.0-70349769195 10.1016/j.surg.2009.06.012
4. Kono T., Kaneko A., Omiya Y., Ohbuchi K., Ohno N., Yamamoto M., Epithelial transient receptor potential ankyrin 1 (TRPA1)-dependent adrenomedullin upregulates blood flow in rat small intestine. American Journal of Physiology 2013 304 4 G428 G436 10.1152/ajpgi.00356.2012
5. Ogasawara T., Marine Y., Ikemoto T., Imura S., Fujii M., Soejima Y., Shimada M., Influence of Dai-kenchu-to (DKT) on human portal blood flow. Hepato-Gastroenterology 2008 55 82-83 574 577 2-s2.0-44349150981 (Pubitemid 351741504)
6. Cameron V. A., Fleming A. M., Novel sites of adrenomedullin gene expression in mouse and rat tissues. Endocrinology 1998 139 5 2253 2264 2-s2.0-0031763330 (Pubitemid 28513745)
7. Kono T., Omiya Y., Hira Y., Kaneko A., Chiba S., Suzuki T., Noguchi M., Watanabe T., Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model. Journal of Gastroenterology 2011 46 10 1187 1196 2-s2.0-84857217763
8. Murata P., Kase Y., Ishige A., Sasaki H., Kurosawa S., Nakamura T., The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats. Life Sciences 2002 70 17 2061 2070 2-s2.0-0037087079 10.1016/S0024-3205(01)01552-1 (Pubitemid 34215131)
9. Kono T., Koseki T., Chiba S., Ebisawa Y., Chisato N., Iwamoto J., Kasai S., Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. Journal of Surgical Research 2008 150 1 78 84 2-s2.0-53249097941 10.1016/j.jss.2008.02.057
10. Brain S. D., Grant A. D., Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiological Reviews 2004 84 3 903 934 2-s2.0-3042597423 10.1152/physrev.00037.2003 (Pubitemid 38823770)
11. Cockcroft J. R., Noon J. P., Gardner-Medwin J., Bennett T., Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. British Journal of Clinical Pharmacology 1997 44 1 57 60 2-s2.0-0030748319 (Pubitemid 27296796)
12. Ashizuka S., Inagaki-Ohara K., Kuwasako K., Kato J., Inatsu H., Kitamura K., Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium. Microbiology and Immunology 2009 53 10 573 581 2-s2.0-73349093417 10.1111/j.1348-0421.2009.00159.x
13. Ashizuka S., Inatsu H., Inagaki-Ohara K., Kita T., Kitamura K., Adrenomedullin as a potential therapeutic agent for inflammatory bowel disease. Current Protein and Peptide Science 2013 14 4 246 255
14. Ashizuka S., Ishikawa N., Kato J., Yamaga J., Inatsu H., Eto T., Kitamura K., Effect of adrenomedullin administration on acetic acid-induced colitis in rats. Peptides 2005 26 12 2610 2615 2-s2.0-27944503407 10.1016/j.peptides.2005. 05.007 (Pubitemid 41676739)
15. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Delgado M., Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006 55 6 824 832 2-s2.0-33646779859 10.1136/gut.2005.084525 (Pubitemid 43764553)
16. Hayashi Y., Narumi K., Tsuji S., Tsubokawa T., Nakaya M.-A., Wakayama T., Zuka M., Ohshima T., Yamagishi M., Okada T., Impact of adrenomedullin on dextran sulfate sodium-induced inflammatory colitis in mice: insights from in vitro and in vivo experimental studies. International Journal of Colorectal Disease 2011 26 11 1453 1462 2-s2.0-80755189935 10.1007/s00384-011-1254-0
17. MacManus C. F., Campbell E. L., Keely S., Burgess A., Kominsky D. J., Colgan S. P., Anti-inflammatory actions of adrenomedullin through fine tuning of HIF stabilization. FASEB Journal 2011 25 6 1856 1864 2-s2.0-79957907499 10.1096/fj.10-170316
18. Talero E., Sánchez-Fidalgo S., de la Lastra C. A., Illanes M., Calvo J. R., Motilva V., Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides 2008 29 11 2001 2012 2-s2.0-54049122543 10.1016/j.peptides.2008.07.013
19. Kono T., Kaneko A., Hira Y., Suzuki T., Chisato N., Ohtake N., Miura N., Watanabe T., Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model. Journal of Crohn's and Colitis 2010 4 2 161 170 2-s2.0-77952108236 10.1016/j.crohns.2009.09.006
20. Hyun E., Andrade-Gordon P., Steinhoff M., Vergnolle N., Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut 2008 57 9 1222 1229 2-s2.0-50249124682 10.1136/gut.2008.150722
21. Kishikawa H., Nishida J., Ichikawa H., Kaida S., Morishita T., Miura S., Hibi T., Lipopolysaccharides stimulate adrenomedullin synthesis in intestinal epithelial cells: release kinetics and secretion polarity. Peptides 2009 30 5 906 912 2-s2.0-67349209560 10.1016/j.peptides.2009.01.023
22. Shen C., De Hertogh G., Bullens D. M. A., Van Assche G., Geboes K., Rutgeerts P., Ceuppens J. L., Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflammatory Bowel Diseases 2007 13 3 308 316 2-s2.0-33947510867 10.1002/ibd.20005 (Pubitemid 46465912)
23. Wang A., Fernando M., Leung G., Phan V., Smyth D., McKay D. M., Exacerbation of oxazolone colitis by infection with the helminth Hymenolepis diminuta: involvement of IL-5 and eosinophils. American Journal of Pathology 2010 177 6 2850 2859 2-s2.0-78650198953 10.2353/ajpath.2010.100537
24. Harrington L. E., Mangan P. R., Weaver C. T., Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Current Opinion in Immunology 2006 18 3 349 356 2-s2.0-33646164439 10.1016/j.coi.2006.03.017
25. Sheikh S. Z., Matsuoka K., Kobayashi T., Li F., Rubinas T., Plevy S. E., Cutting edge: IFN- γ is a negative regulator of IL-23 in murine macrophages and experimental colitis. Journal of Immunology 2010 184 8 4069 4073 2-s2.0-77952784918 10.4049/jimmunol.0903600
26. Otley A. R., Russell R. K., Day A. S., Nutritional therapy for the treatment of pediatric Crohns disease. Expert Review of Clinical Immunology 2010 6 4 667 676 2-s2.0-77954411180 10.1586/eci.10.37
27. Ferguson L. R., Nutrigenomics and inflammatory bowel diseases. Expert Review of Clinical Immunology 2010 6 4 573 583 2-s2.0-77954398661 10.1586/eci.10.43
28. Vanderpool C., Yan F., Polk D. B., Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflammatory Bowel Diseases 2008 14 11 1585 1596 2-s2.0-59249100550 10.1002/ibd.20525
29. Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y., Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. Journal of Pharmacology and Experimental Therapeutics 2005 315 1 196 202 2-s2.0-25644442467 10.1124/jpet.105.088146 (Pubitemid 41380512)
30. Fichtner-Feigl S., Fuss I. J., Preise J. C., Strober W., Kitani A., Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF- B decoy oligonucleotides. Journal of Clinical Investigation 2005 115 11 3057 3071 2-s2.0-27644453163 10.1172/JCI24792 (Pubitemid 41567571)
31. De Vry C. G., Prasad S., Komuves L., Lorenzana C., Parham C., Le T., Adda S., Hoffman J., Kahoud N., Garlapati R., Shyamsundar R., Mai K., Zhang J., Muchamuel T., Dajee M., Schryver B., McEvoy L. M., Ehrhardt R. O., Non-viral delivery of nuclear factor- B decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007 56 4 524 533 2-s2.0-34147207287 10.1136/gut.2006.096487 (Pubitemid 46580509)
32. Sun X., Somada S., Shibata K., Muta H., Yamada H., Yoshihara H., Honda K., Nakamura K., Takayanagi R., Tani K., Podack E. R., Yoshikai Y., A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 2008 134 2 447 458 2-s2.0-38649135387 10.1053/j.gastro.2007.11. 004 (Pubitemid 351173042)
33. Caruso R., Sarra M., Stolfi C., Rizzo A., Fina D., Fantini M. C., Pallone F., MacDonald T. T., Monteleone G., Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 2009 136 7 2270 2279 2-s2.0-66149156478 10.1053/j.gastro.2009.02.049
34. Batra A., Okur B., Glauben R., Erben U., Ihbe J., Stroh T., Fedke I., Chang H.-D., Zeitz M., Siegmund B., Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo. Endocrinology 2010 151 1 56 62 2-s2.0-73649112416 10.1210/en.2009-0565
35. Mencarelli A., Renga B., Palladino G., Distrutti E., Fiorucci S., The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochemical Pharmacology 2009 78 9 1214 1223 2-s2.0-70249103784 10.1016/j.bcp.2009.06.026
36. Calixto J. B., Kassuya C. A. L., André E., Ferreira J., Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. Pharmacology and Therapeutics 2005 106 2 179 208 2-s2.0-18044389382 10.1016/j.pharmthera.2004.11. 008 (Pubitemid 40603864)
37. Camelo A., Barlow J. L., Drynan L. F., Neill D. R., Ballantyne S. J., Wong S. H., Pannell R., Gao W., Wrigley K., Sprenkle J., McKenzie A. N. J., Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. Journal of Gastroenterology 2012 47 11 1198 1211 2-s2.0-84860193198 10.1007/s00535-012- 0591-2
38. Koga K., Takaesu G., Yoshida R., Nakaya M., Kobayashi T., Kinjyo I., Yoshimura A., Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009 30 3 372 383 2-s2.0-62049085056 10.1016/j.immuni.2008.12.021
39. Wilhelm S. M., McKenney K. A., Rivait K. N., Kale-Pradhan P. B., A review of infliximab use in ulcerative colitis. Clinical Therapeutics 2008 30 2 223 230 2-s2.0-41549090435 10.1016/j.clinthera.2008.02.014 (Pubitemid 351474384)
40. Liao W., Lin J. X., Leonard W. J., Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013 38 1 13 25
41. Marutsuka K., Nawa Y., Asada Y., Hara S., Kitamura K., Eto T., Sumiyoshi A., Adrenomedullin and proadrenomudullin N-terminal 20 peptide (PAMP) are present in human colonic epithelia and exert an antimicrobial effect. Experimental Physiology 2001 86 5 543 545 2-s2.0-0034802638 10.1113/eph8602250 (Pubitemid 32910341)
42. van Breemen R. B., Tao Y., Li W., Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia 2011 82 1 38 43 2-s2.0-79151481756 10.1016/j.fitote.2010.09.004
43. Nievergelt A., Marazzi J., Schoop R., Altmann K.-H., Gertsch J., Ginger phenylpropanoids inhibit IL-1 β and prostanoid secretion and disrupt arachidonate-phospholipid remodeling by targeting phospholipases A2. Journal of Immunology 2011 187 8 4140 4150 2-s2.0-80054769765 10.4049/jimmunol.1100880
44. Lü J.-M., Yao Q., Chen C., Ginseng compounds: an update on their molecular mechanisms and medical applications. Current Vascular Pharmacology 2009 7 3 293 302 2-s2.0-69149110615 10.2174/157016109788340767